Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

6 terminated/withdrawn out of 9 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

350%

7 of 2 completed trials have results

Key Signals

7 with results6 terminated

Enrollment Performance

Analytics

Phase 1

8(88.9%)

Phase 2

1(11.1%)

9Total

Phase 1(8)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05605509Phase 2Completed

RP-6306 in Patients With Advanced Cancer

Role: collaborator

NCT06560632Phase 1Terminated

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

Role: lead

NCT05566574Phase 1Active Not Recruiting

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Role: collaborator

NCT05147350Phase 1Terminated

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

Role: collaborator

NCT05147272Phase 1Terminated

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Role: collaborator

NCT06232408Phase 1Terminated

LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

Role: lead

NCT04972110Phase 1Terminated

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

Role: lead

NCT04497116Phase 1Completed

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Role: lead

NCT05405309Phase 1Terminated

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Role: collaborator

All 9 trials loaded